Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial

Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial

Background. Tofacitinib is an oral Janus kinase inhibitor. This open-label, long-term extension (LTE) study (NCT00658359) evaluated long-term tofacitinib treatment in stable kidney transplant recipients (n = 178) posttransplant. Methods. Patients who completed 12 months of cyclosporine (CsA) or tofa...

Full description

Bibliographic Details
Main Authors: Stephan Busque, MD, MSc, FRCSC, Flavio G. Vincenti, MD, Helio Tedesco Silva, MD, Philip J. O’Connell, MD, Atsushi Yoshida, MD, John J. Friedewald, MD, Steven M. Steinberg, MD, Klemens Budde, MD, Emine N. Broeders, MD, Yon Su Kim, MD, Carolyn M. Hahn, BA, Huihua Li, MS, Gary Chan, PharmD
Format: Article
Language:English
Published: Wolters Kluwer 2018-09-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000000819

Internet

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000000819

Similar Items